Clinical Trials Browser

Hodgkin Disease, Recurrence

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Hodgkin Disease

Breast Neoplasms

Breast Neoplasms

Lung Diseases, Interstitial

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Rhabdomyosarcoma, Sarcoma

Breast Neoplasms, Neoplasms

Rhabdomyosarcoma

Colonic Neoplasms

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Breast Neoplasms

HER2-negative Metastatic Breast Cancer

Hodgkin Disease

Breast Neoplasms

Breast Neoplasms

Multiple Myeloma

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Recurrence, Lymphoma, Large-Cell, Anaplastic

Breast Neoplasms

HER2-negative Breast Cancer

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Her2-negative Metastatic Breast Cancer

Breast Neoplasms

Advanced Breast Cancer

Advanced Non-Small Cell Lung Cancer

Breast Neoplasms

Lethal Congenital Contracture Syndrome 2

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Triple Negative Breast Neoplasms

Lung Neoplasms

Diffuse Intrinsic Pontine Glioma

Breast Neoplasms

Hodgkin Disease, Lymphoma, Recurrence

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Metastatic

Advanced Breast Cancer

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

ASPEN-09-03

IMMUNOLIFE2

CAMPFIRE

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

AZALEA

BRIDGE

TrasTUCAN

Evolutionary Therapy for Rhabdomyosarcoma

ATREZZO

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

EORTC1616

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

PemVin vs Vin in Previously Treated Metastatic Breast Cancer

ORCHID

MOCCCA

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Vinorelbine for Recurrent ALCL-2017

SAFIR02_Breast

ORIENTA

SPRING

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

EASOVCWDITHABC

RIGHT Choice

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

METEORA-II

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

NORA

DIPG

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

CHEOPS

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

VEX

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

DURATION